We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    HORA EST
Previous Study | Return to List | Next Study

Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study (HORA EST HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03437382
Recruitment Status : Completed
First Posted : February 19, 2018
Last Update Posted : March 18, 2021
Sponsor:
Collaborators:
ZonMw: The Netherlands Organisation for Health Research and Development
Health Holland
Quirem Medical B.V.
Medtronic
Maag Lever Darm Stichting
Information provided by (Responsible Party):
MCBurgmans, Leiden University Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
In this multi-center, dose-finding study, patients with early stage hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer (BCLC) staging system will be included to receive percutaneous radiofrequency ablation in combination with RFA with adjuvant segmental radioembolization.

Condition or disease Intervention/treatment Phase
HCC Early Stage HCC Device: Quirem Medical Holmium-166 radioembolization microspheres Not Applicable

Detailed Description:
RFA + adjuvant radioembolsation with Quirem Spheres
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: single-arm, interventional, dose escalation study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: HOlmium Radioembolization as Adjuvant Treatment to Radiofrequency Ablation for Early STage Hepatocellular Carcinoma (HORA EST HCC)
Actual Study Start Date : July 1, 2018
Actual Primary Completion Date : March 17, 2021
Actual Study Completion Date : March 17, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Holmium

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
RFA + radioembolization
Quirem Medical Holmium-166 radioembolization microspheres
 Device: Quirem Medical Holmium-166 radioembolization microspheres
radioembolisation as adjuvant treatment to RFA


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Dose-finding [ Time Frame: 1 year ]
    Treatment area dose that will result in delivery of a radiation absorbed dose of ≥ 120Gy to the target area in at least 90% of patients.


Secondary Outcome Measures :
  1. Toxicity [ Time Frame: 1 year ]
    Toxicity of RFA with adjuvant segmental radioembolization as assessed by complications according to CTCAE v4.0

  2. Local tumor recurrence [ Time Frame: 6 months and 12 months ]
    Local tumor recurrence at 6 months as assessed by multiphase CT or dynamic MRI

  3. Time to progression [ Time Frame: 1 year ]
    time until disease progresses

  4. Progression-free survival [ Time Frame: 1 year ]
    Kaplan-Meier analysis of progression free survival

  5. Quality of Life [ Time Frame: Throughout the first year after treatment. ]
    Quality of Life will be assessed by means of the EORTC QLQ HCC-18 questionnaire

  6. Quality of Life [ Time Frame: Throughout the first year after treatment. ]
    Quality of Life will be assessed by means of the C-30 questionnaire


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed consent
  • Age > 18 years
  • Single HCC lesion with diameter of ≥ 2-5cm or up to three lesions with each lesion measuring no more than 3cm (confined to one lobe)
  • HCC diagnosis is based on histology or non-invasive imaging criteria according to EORTC-EASL guidelines
  • Child Pugh A or B ≤7
  • ECOG performance status ≤ 2
  • Bilirubin < 2mg/dL
  • ASAT < 5x upper limit of normal
  • ALAT < 5x upper limit of normal
  • Thrombocytes ≥ 50 X 10^9/L

Exclusion Criteria:

  • Recurrent HCC
  • Tumor location precluding percutaneous RFA
  • Bilobar tumor involvement
  • Vascular tumor invasion or extrahepatic metastasis
  • Hemihepatectomy
  • Severe comorbidity (e.g. cardiovascular disease, diabetes with nephropathy, active infections)
  • Uncorrectable coagulopathy
  • Large arterio-portovenous shunt
  • Previous radiotherapy to the liver
  • Surgical hepatico-enterostomy
  • Hepatic resection with placement of surgical clips that may cause artefacts on MRI
  • Incompetent/ mentally disabled
  • Pregnancy, inadequate anticonception
  • Calculated lung dose >30Gy
  • Creatinine clearance < 50 ml/min
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03437382


Locations
Layout table for location information
Netherlands
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands, 2333ZA
Sponsors and Collaborators
Leiden University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Health Holland
Quirem Medical B.V.
Medtronic
Maag Lever Darm Stichting
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: MCBurgmans, Principle Investigator, Leiden University Medical Center
ClinicalTrials.gov Identifier: NCT03437382    
Other Study ID Numbers: P17.161
ZonMW ( Other Grant/Funding Number: PTO 2017 - 40-41200-98-9286 )
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: March 18, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MCBurgmans, Leiden University Medical Center:
Hepatocellular carcinoma
Radiofrequency ablation (RFA)
Radioembolization
Quirem Spheres
Selective internal radiation therapy